Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "Biopharma"

861 News Found

GCCL and OPIS forge global clinical trial alliance
Clinical Trials | January 17, 2026

GCCL and OPIS forge global clinical trial alliance

GCCL aims to leverage the partnership to expand strategic relationships with global CROs


Vetter advances next-gen syringe closure system towards 2027 launch
Medical Device | January 16, 2026

Vetter advances next-gen syringe closure system towards 2027 launch

The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats


Bayer acquires Attralus’ cardiac amyloidosis imaging agents
News | January 16, 2026

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology


Biocon completes Rs. 4,150 crore equity fundraise through QIP
News | January 15, 2026

Biocon completes Rs. 4,150 crore equity fundraise through QIP

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited


BioNTech maps pivotal oncology milestones for 2026
News | January 15, 2026

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company


BD announces $110 million investment in Nebraska to expand prefillable syringe production
News | January 15, 2026

BD announces $110 million investment in Nebraska to expand prefillable syringe production

The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products


Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
News | January 14, 2026

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics


MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
Clinical Trials | January 12, 2026

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms